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Summary 
Transgenic (Tg) mice expressing human (Hu) and chi- 
merit prion protein (PrP) genes were inoculated with 
brain extracts from humans with inherited or sporadic 
prion disease to investigate the mechanism by which 
PrPC is transformed into PrPSc. Although Tg(HuPrP) 
mice expressed high levels of HuPrPC, they were resis- 
tant to human prions. They became susceptible to hu- 
man prions upon ablation of the mouse (MO) PrP gene. 
In contrast, mice expressing low levels of the chimeric 
transgene were susceptible to human prionsand regis- 
tered only a modest decrease in incubation times upon 
MoPrP gene disruption. These and other findings ar- 
gue that a species-specific macromolecule, provision- 
ally designated protein X, participates in prion forma- 
tion. While the results demonstrate that PrPSC binds to 
PrPC in a region delimited by codons 96 to 167, they 
also suggest that PrPC binds protein X through resi- 
dues near the C-terminus. Protein X might function as 
a molecular chaperone in the formation of PrPSc. 
Introduction 
For three decades, the transmission of human prion dis- 
eases was studied largely with apes and monkeys, in 
which >90% of cases are thought to be transmissible 
(Brown et al., 1994; Gajdusek et al., 1966). Inoculations 
of mice, rats, and hamsters produced variable results 
(Manuelidis et al., 1978; Tateishi and Kitamoto, 1995; Ta- 
teishi et al., 1983). In our experience, only - 10% of intra- 
cerebrally inoculated mice developed central nervous sys- 
tem (CNS) dysfunction, with incubation times of >500 days 
(Prusiner, 1987; Telling et al., 1994). Since previous inves- 
tigations had shown that the “species barrier” between 
mice and Syrian hamsters for the transmission of prions 
can be abrogated by expression of a Syrian hamster (SHa) 
prion protein (PrP) transgene in mice (Scott et al., 1989), 
transgenic (Tg) mice expressing human (Hu) PrP were 
constructed. These Tg(HuPrP) mice expressed levels of 
the human cellular prion protein, denoted HuPrPC, that 
were 4- to 8-fold higher than those of endogenous mouse 
(MO) PrPC, yet upon inoculation with human prions they 
failed to develop CNS dysfunction more frequently than 
nontransgenic controls (Telling et al., 1994). 
Because of the resistance of Tg(HuPrP) mice to human 
prions, we constructed mice expressing a chimeric Hul 
MoPrP transgene, designated MHu2M. Earlier studies 
had shown that chimeric SHalMoPrP transgenes sup- 
ported transmission of either mouse or Syrian hamster 
prions (Scott et al., 1992, 1993). The Tg(MHu2M) mice 
expressing the chimeric transgene at a level slightly below 
that of endogenous MoPrPC were found to be highly sus- 
ceptible to human prions, suggesting that Tg(HuPrP) mice 
have considerable difficulty converting HuPrPC into the 
scrapie isoform, designated PrPSc (Telling et al., 1994). 
Although MoPrP and HuPrP differ at 28 residues, only 
nine or perhaps fewer amino acids in the region between 
codons 96 and 167 feature in the species barrier in the 
transmission of human prions into mice, as demonstrated 
by the susceptibility of Tg(MHu2M) mice to human prions. 
To explore why human prions transmit disease to 
Tg(MHu2M) mice expressing chimeric PrP but not to 
Tg(HuPrP) mice, we crossed Tg(HuPrP)FVB mice with 
those in which the MoPrP gene had been ablated, desig- 
nated PrnpO’o(Btieleretal., 1992). TheresultingTg(HuPrP) 
Prnp’” mice were found to be susceptible to human prions, 
whereas Tg(MHu2M)Prnp”‘0 mice were rendered only 
slightly more susceptible. These observations indicate that 
MoPrPC inhibited the conversion of HuPrPC into PrPSc and 
that inhibition was abolished once MoPrPC was removed 
by gene ablation. 
The foregoing results suggest that two separate do- 
mains of HuPrPC participate in the formation of PrP? the 
central domain delimited by codons 96 to 167 defined by 
the human sequence in chimeric MHu2M PrPC that binds 
to PrPSc and an additional domain through which HuPrPC 
binds to a macromolecule other than PrPSc. We assume 
that this macromolecule is a protein and have provisionally 
designated it “protein X.” From our chimeric transgene 
studies, the second domain of PrPC must be at the N- or 
C-terminus, i.e., outside the central region of PrP. Like 
the binding of PrPC to PrPSC, which is most efficient when 
the two isoforms have the same sequence (Prusiner et 
al., 1990), the binding of PrPC to protein X seems to exhibit 
the highest affinity when these two proteins are from the 
same species. Although the level of MoPrPC could be re- 
duced to as low as 5%-10% of HuPrPC in the brains of 
the Tg(HuPrP) mice, it prevented the conversion of 
HuPrPC into PrPSc. These findings suggest that MoPrPC 
binds to mouse protein X with a considerably higher affinity 
than does HuPrPC, which provides an explanation for why 
MoPrPC inhibits the transmission of human prions in 
Tg(HuPrP) mice. 
Since truncation of the N-terminus of recombinant PrP 
expressed in cultured cells still permitted the formation of 
PrPsc-like molecules (Rogers et al., 1993), it seems likely 
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that the site at which PrPC binds to another protein is at 
the C-terminal end of PrPC. Mature HuPrP differs from 
MoPrP at only five positions at the C-terminus lying be- 
tween residues 215 and 230, some of which are likely to 
form the protein X-binding site for PrPC. 
The proposed model for prion propagation involving pro- 
tein X is supported by studies on an inherited form of prion 
disease modeled in mice. Spontaneous CNS disease was 
found in uninoculated mice expressing the P102L point 
mutation of Gerstmann-Straussler-Scheinker (GSS) dis- 
ease when this substitution was introduced into MoPrP 
(Hsiao et al., 1994). As reported here, the Pi 02L mutation 
expressed in chimeric MHu2M PrP but not in HuPrP pro- 
duced CNSdysfunction in transgenic mice. These findings 
argue that, like the transmissible disorder, inherited prion 
disease requires protein X for the conversion of mutant 
PrPC into a pathologic isoform. 
Our  results argue that the C-terminus of PrPC binds to 
protein X, while the central domain binds to PrPSc. Mis- 
matches in amino acids between the two isoforms at resi- 
dues 102 and 129, which lie within the central domain, 
resulted in delayed onset of CNS dysfunction, whereas a 
mismatch outside this domain at position 200 did not. 
Results 
Transgenic Mice with Human and Chimeric 
PrP Genes 
FVBmiceexpressing human, chimeric Hu/Mo, and mutant 
PrP genes were constructed using the cos.SHaTet cosmid 
expression vector (Scott et al., 1992). Table 1 shows the 
designation of the mouse line, the expressed PrPC mole- 
cules, and the approximate level of transgene expression. 
Also indicated are those mouse lines that were crossed 
with PrnpO’O  mice in which the MoPrP gene had been dis- 
rupted (Bueler et al., 1992). 
Since the human prion inocula are brain homogenates 
or purified prion rods from a variety of patients who died 
of prion disease, the designations for the patients as well 
as clinical phenotypes are listed in Table 2. 
MoPrPC Inhibits Propagation of Human Prions 
in Tg(HuPrP) Mice 
When Tg(HuPrP)152/FVB mice and nontransgenic lit- 
termates were inoculated with human prionsfrom sporadic 
or iatrogenic Creutzfeldt-Jakob disease (CJD) as well as 
inherited prion disease cases, -10% of each group of 
mice developed CNS dysfunction (Telling et al., 1994). 
Some of the ill mice produced MoPrPSc and others pro- 
duced HuPrPSc, based on Western immunoblots devel- 
oped with polyclonal anti-PrP antiserum that reacts with 
both HuPrP and MoPrP and anti-PrP monoclonal antibod- 
ies (MAbs) that react with HuPrP but not MoPrP. Those 
mice that produced HuPrPSc demonstrated that HuPrPSc 
could be formed in mouse cells, but the process was too 
infrequent for further study. 
After the Tg(HuPrP)152/FVB mice were crossed onto 
the Prnp”‘O  background, they became susceptible to hu- 
man prions(Table3). When Tg(HuPrP)152/FVB mice were 
inoculated with human prions from acase of sporadic CJD, 
referred to as RG, only one transgenic mouse out of a 
group of ten developed neurologic symptoms at >720 
days; nontransgenic littermates responded similarly, with 
one animal out of a group of ten inoculated mice devel- 
oping neurologic symptoms at >700 days. Similar rates 
of transmission were observed when Tg(HuPrP)152/FVB 
and nontransgenic mice were inoculated with a prepara- 
tion highly enriched for PrPSc prepared from the brain of 
RG (Table 3, top). By serial dilution and dot immunoblot- 
ting of brain homogenates normalized for protein concen- 
tration, we estimated the level of HuPrPC in the brains 
of the Tg(HuPrP)152/FVB mice to be approximately 4- to 
&fold higher than HuPrPC in human brain using the anti- 
PrP 3F4 MAb (Table 1) (Kascsak et al., 1987). 
Since earlier studies had shown that heterologous PrPc 
inhibited the conversion of PrPC homologous to inoculated 
PrPSc, as manifested by prolongation of the incubation 
time (Bfieler et al., 1993; Prusiner et al., 1990, 1993), we 
removed MoPrPC by producing Tg(HuPrP)152/Prnp”’ 
mice. When Tg(HuPrP)1521Prnp”‘o mice were inoculated 
with human prions, they developed signs of neurologic 
Table 1. Characteristics of Transgenic Mouse Lines 
Expressed PrP Transgene 
Mouse Line PrPC Expression 
Designation Molecules (Fold) Sequenceb 
Tg(HuPrP) mice 
Tg(HuPrP)152/FVB Hu, MO - 4-8 v129 
Tg(HuPrP)152/Prnp0’0 Hu - 4-8 VI29 
Tg(HuPrP)152/Prnp+‘O Hu, MO” - 4-8 v129 
Tg(HuPrP)440/Prnp0’0 Hu -2 Ml29 
Tg(MHu2M) mice 
Tg(MHu2M)5378/FVS MHuSM, MO -1 Ml28 
Tg(MHu2M)5378/PrnpW0 MHu2M -1 Ml28 
Tg(MHu2M-PI01 L)69/Prnp”‘0 MHu2M-Ld -2 M126, L101 
a Level of PrP transgene expression in brain was measured by serial dilution of the samples, followed by dot immunoblotting. Each sample was 
compared to PrPC in human brain. 
b Amino acid residues at codon 129 (codon 126 in MoPrP) or codon 101. 
c Tg(HuPrP)PrnpQ mice are hemizygous for disruption of the MoPrP gene and express -50% less MoPrPC than wild-type mice (Siieler et al., 
1992). 
d L indicates substitution of L for P at codon 101 in chimeric MHu2MPrP. 
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Table 2. Characteristics of Human Prion lnocula 
Human lnocula Prion Disease Genotype of PrP” 
Sporadic and infectious CJD prions containing wild-type PrPSc 
RG, EC, MA, RO Sporadic CJD M/M 129 
RC Sporadic CJD ND 
364 latrogenic CJD M/M 129 
GSS and familial CJD prions containing mutant PrPSc 
JJ GSS P102L, v/V 129 
Wl, CA Familial CJD E200K, M/M 129 
FH Familial CJD E200K, MN 129 
a Patients with sporadic or iatrogenic CJD had wild-type PrP open reading frames. The PrP alleles encode either M  or V at position as noted. 
Mutations in the PrP gene are denoted by the wild-type amino acid followed by the codon number and the mutant residue. ND, not determined. 
dysfunction with incubation times of - 260 days (Table 3, 
middle). 
Tg(HuPrP)152/Prnp+‘” mice, which are hemizygous for 
disruption of the MoPrP gene, express about 50% of the 
MoPrPC found in control mice (Btieler et al., 1992). Like 
Tg(HuPrP)152/FVB mice, these mice are resistant to hu- 
man prions (Table 3, bottom). 
MoPrP Gene Ablation in Mice Expressing 
Chimeric PrP 
Crossing the transgene array from the already susceptible 
Tg(MHu2M)FVB mice onto the Prnp”” background re- 
sulted in only a modest decrease (- 20%) in CJD incuba- 
tion times (Table 4, top and middle). Using the 3F4 MAb, 
we estimated the level of MHu2M PrPC in the brains of 
the Tg(MHu2M)FVB mice to be slightly less than HuPrPC 
in human brain. 
Any comparison between the incubation times of 
Tg(HuPrP)152/Prnp”” and Tg(MHu2M)PrnpO’O  mice must 
take into account the different levels of transgene expres- 
sion. Generally, the level of transgene expression is in- 
versely related to the length of the incubation time (Prusi- 
ner et al., 1990). Although the incubation times are similar 
for Tg(HuPrP)152/Prnp”‘o and Tg(MHu2M)Prnp”‘0 mice in- 
oculated with human prions (Table 3, middle and Table 
Table 3. Transmission of Human Prions to Tg(HuPrP)PrnpO’n Mice 
Incubation Time in 
Recipient Mouse Line lnoculuma Mean Days f SEM(n/n,) 
Tg(HuPrP)FVB mice 
Tg(HuPrP)152/FVB sCJD (RG) 721 (l/10) 
Nontransgenic 152/FVB sCJD (RG) 701 (l/iO)b 
Tg(HuPrP)152/FVB sCJD (RG, purified rods) 677 (111O)b 
Nontransgenic 152/FVB sCJD (RG, purified rods) 643 f 42 (3/10)b 
Tg(HuPrP)PrnpO” mice 
Tg(HuPrP)152/Prnp0’0 sCJD (RG) 263 & 2 034 
Tg(HuPrP)152/Prnp”‘0 sCJD (EC) 254 f 6 W) 
Tg(HuPrP)152/Prnpof0 iCJD (364) 262 f 8 (64 
Tg(HuPrP)440/PrnpO’O iCJD (364) 164 k 2 (717) 
Tg(HuPrP)Prnp+‘” mice 
Tg(HuPrP)152/Prnp+‘0 sCJD (RG) >370 VW 
Tg(HuPrP)152/Prnp+” iCJD (364) >400 (014) 
a All samples were 10% (w/v) brain homogenates, unless otherwise noted, that were diluted 1:lO prior to inoculation. sCJD is sporadic CJD, and 
iCJD is iatrogenic CJD. The initials of patients referring to inocula in Table 2 are given in parentheses. 
b Extended observations of transmissions previously reported (Telling et al., 1994). 
4, middle), the Tg(HuPrP)152/Prnp0’0 mice express 5- to 
lo-fold more of the transgene product than Tg(MHu2M) 
PrnpO’O  mice. This suggests that the chimeric transgene 
or some modified version may be superior to HuPrP in 
terms of generating mice with the shortest incubation 
times for bioassay of human prions. 
Transmission of Chimeric Prions 
Species-specific amino acid variations in PrP are known 
to contribute significantly to the species barrier (Pattison, 
1965; Prusiner et al., 1990; Scott et al., 1989). Primary 
passage of human prions from a sporadic CJD case, re- 
ferred to as EC, in Tg(MHu2M)FVB mice with an incuba- 
tion time of 218 days (Table 4, top) demonstrated that the 
central region of MHuPM PrPC conferred susceptibility. To 
determine whether sequences outside this region contrib- 
uted to the efficiency of transmission, brains from ill mice 
were collected, and homogenates were inoculated into 
mice from the same transgenic line. Passage of these 
chimeric prions in Tg(MHu2M)FVB mice gave incubation 
times similar to those seen with human prions on the pri- 
mary passage (Table 5, top). This finding shows that 
Tg(MHu2M)FVB mice are permissive for human prions. 
Passage of chimeric prions in Tg(MHu2M)Prnpoio mice re- 
sulted in a shortening of the incubation time by -2O%, 
presumably owing to the elimination of MoPrPC. 
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Table 4. Transmission of Human Prions to Tg(MHu2M PrP) Mice 
lnoculuma 
Incubation Time in 
Mean Days f SEM (n/no) 
Tg(MHu2M)FVB mice inoculated with sporadic or infectious CJD 
sCJD (RG) 238 f 3 (8/8)b 
sCJD (EC) 218 + 5 (7/7)b 
iCJD (364) 232 + 3 (9/9)b 
iCJD (364) 231 * 6 (9/9) 
sCJD (MA) 222 f 1 (4/4) 
Tg(MHu2M)Prnp”‘0 mice inoculated with sporadic or infectious CJD 
sCJD (WC) 207 f 4 (E/10) 
sCJD (RG) 191 + 3 (10/10) 
iCJD (364) 192 f 6 (8/a) 
iCJD (364) 211 f 5 (8/9) 
sCJD (MA) 180 f 5 (8/8) 
sCJD (RO) 217 f 2 (9/9) 
Tg(MHu2M)PrnpWo mice inoculated with inherited GSS or CJD 
GSS (JJ,PlOPL) >310 (0110) 
fCJD (LJl,E200K) 170 f 2 (10/10) 
fCJD (CAE200K) 180 f 9 (9/9) 
fCJD (FH,E200K) >290 (017) 
a All samples were 10% (w/v) brain homogenates, unless otherwise noted, that were diluted 1 :I0 prior to inoculation. sCJD is sporadic CJD, and 
iCJD is iatrogenic CJD. GSS is Gerstmann-Straussler-Scheinker disease with the codon 102 mutation, and fCJD is familial CJD with the codon 
200 mutation. The initials of patients referring to inocula in Table 2 are given in parentheses. If the PrP gene of the patient carried a mutation, 
then the mutation is noted after the initials of the patient. 
b Transmissions previously reported (Telling et al., 1994). 
c This is a second inoculum prepared from a different brain region of iatrogenic CJD patient 364. 
Table 5. Serial Transmission of Chimeric HulMo Prions in Tg(MHu2M) Mice 
Incubation Times in Mean Days f 
SEM (n/n.) 
Recipient Mouse Line lnoculuma Illness Death 
Chimeric prions produced in Tg(MHu2M) mice inoculated with CJD prions 
Tg(MHu2M)5378/FVB MHu~M(sCJD)~ 220 f 3 (7/7) 226 f 1 (5) 
Nontransgenic 5378/FVB MHu~M(sCJD)~ >420 (015) 
Tg(MHu2M)5378/FVB MHu2M(sCJDr 226 f 3 (919) 228 + 1 (6) 
Nontransgenic 5378/FVB MHu~M(sCJD)~ >420 (015) 
Tg(MHu2M)5378/Prnp0”’ MHu~M(sCJD)~ 189 f 4 (8/E) 192 f 1 (4) 
Tg(MHu2M)5378/Prnp0” MHu~M(sCJD)~ 183 f 5(7/7) 190 f 3 (4) 
Mouse prions produced in Tg(MHu2M) or nontransgenic mice inoculated 
with RML prions 
Tg(MHu2M)5378/FVB Mo(RML) 178 f 3 (19/19) 203 + 2 (14) 
Nontransgenic 5378/FVB Mo(RML) 127 + 2 (18/18) 156 f 2 (5) 
Tg(MHu2M)5378/FVB MHu2M(RML)’ 185 f 1 (7/7) 211 f 1 (3) 
Tg(MHu2M)5378/FVB MHu2M(RML)g 189 -t 2 (7/7) 211 f 9 (3) 
Nontransgenic 53781FVB MHu2M(RML)s 134 f 3 (5/5) ND 
Tg(MHu2M)5378/Prnp0’0 Mo(RML) >420 (017) 
Tg(MHu2M)5378/Prnp0’0 MHu2M(RML) >380 (O/i 0) 
Tg(MHu2M)5378/Prnpn”’ MHu2M(RML)g >380 (O/l 0) 
a Notation in parentheses indicates inoculum used in initial passage in Tg(MHu2M) mice. 
b Mice were inoculated with chimeric prions generated in the brain of a Tg(MHu2M)5378/FVB mouse that had been inoculated with a brain 
homogenate prepared from patient EC who died of sporadic CJD. 
c Number of mice developing CNS illness divided by the number inoculated is given in parentheses. 
d Mice were inoculated with chimeric prions generated in the brain of a second Tg(MHu2M)5378/FVB mouse that had been inoculated with a brain 
homogenate prepared from patient EC who died of sporadic CJD. 
e Data from Telling et al. (1994). 
‘ Mice were inoculated with mouse prions generated in the brain of a Tg(MHu2M)5378/FVB mouse that had been inoculated with RML mouse 
prions. 
9 Mice were inoculated with mouse prions generated in the brain of a second Tg(MHu2M)5378/FVB mouse that had been inoculated with RML 
mouse prions. 
ND, not determined. 
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Time after inoculation (days) 
Figure 1. Amino Acid Mismatches at the Codon 129 Polymorphism 
Prolong the Incubation Times of Tg(HuPrP)PrnpO” Mice 
Tg(HuPrP-M129)440/Pmp0’0micewere inoculated intracerebrally with 
acaseof iatrogenicCJD(364A, triangles). Tg(HuPrP-V129)152/Pmp010 
mice were inoculated with iatrogenic CJD (364A, diamonds) and spo- 
radic CJD (EC, squares; RG, circles). All the CJD cases were from 
individuals homozygous for M/M at codon 129. 
Specificity of Chimeric Prions and Transgenes 
While nontransgenic mice expressing only MoPrPC are 
resistant to chimeric prions, Tg(MHu2M)PrnpO” mice ap- 
pear to be unaffected by mouse prions. At the time of 
writing, both groups of mice remain well at >420 days after 
inoculation (Table 5). These observations, along with the 
serial passaging experiments, provide strong support for 
the hypothesis that homology between PrPC and PrPSc in 
the region bounded by residues 96 and 167 facilitates 
prion propagation. 
Although Tg(MHu2M)FVB mice are permissive for 
Mo(RML) prions, the incubation time of - 178 days was 
protracted compared with that of 127 days for non- 
transgenic littermates (Table 5, middle). Two homoge- 
nates derived from Tg(MHu2M)FVB mice inoculated with 
Mo(RML) prions were passaged in the same line of 
transgenic mice, nontransgenic littermates and Tg(MHu2M) 
Prnp”O  mice. The incubation time in Tg(MHu2M)FVB mice 
did not change, while the incubation time in the non- 
transgenic mice shortened to that registered for primary 
passage of Mo(RML) prions in these mice (Table 5, mid- 
dle). This behavior, and the fact that MoPrPSc is made in 
response to inoculation with mouse prions (Telling et al., 
1994), argues that Tg(MHu2M)FVB mice propagate mouse 
prions from endogenous MoPrPC and not from MHuPM 
PrPC. Conversely, Tg(MHu2M)PrnpO” mice were resistant 
to mouse prions; they have remained well for >340 days 
after inoculation (Table 5, middle). 
Residue 129 Mismatches between PrPSc in the 
lnoculum and Transgene-Encoded PrPC 
In Caucasians (Palmer et al., 1991), but not Asians (Ta- 
teishi and Kitamoto, 1993), homozygosity for M  or V at 
codon 129 has been reported to predispose people to de- 
velopment of sporadic CJD. The Tg(HuPrP)152 mice ex- 
press HuPrP with V at codon 129, while another line, 
Tg(HuPrP)440, synthesizes HuPrP with M  at 129. When 
Tg(HuPrP)152/Prnp0/0 and Tg(HuPrP)440/Prnp0” mice were 
inoculated with prions from iatrogenic and sporadic CJD 
cases, the shortest incubation times occurred when the 
amino acid residues at position 129 were the same in PrPC 
ox 
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Figure 2. Spontaneous and Transmissible Neurodegeneration in 
Tg(MHu2M-P102L)69/Prnp”‘0 Mice 
Uninoculated Tg(MHu2M-P102L)69/PrnpO” mice were observed for 
thespontaneousdevelopmentof neurologicdisease(squares). At -70 
days of age, Tg(MH~2M-P102L)69/Prnp~‘~ mice were inoculated intra- 
cerebrally with brain homogenate prepared from either a patient with 
GSS who carried the P102L mutation (diamonds) or another patient 
who died of sporadic CJD (triangles). 
and inoculated PrPSc (Figure 1). Tg(HuPrP)440/Prnp”‘o mice 
inoculated with a case of iatrogenic CJD from a patient 
with an M/M codon 129 haplotype, referred to as case 
364, exhibited a mean incubation time of 164 days, while 
the same inoculum produced disease in Tg(HuPrP)152/ 
PrnpO’O  mice with a mean incubation time of 253 days, Two 
cases of sporadic CJD derived from patients with the M/M 
codon 129 haplotype (EC and RG) produced disease in 
Tg(HuPrP)152/Prnp”‘o mice with mean incubation times of 
254 and 263 days, respectively (Table 3, middle). 
Tg(MHu2M-Pl Ol L) Mice Expressing 
the GSS Mutation 
In our initial studies designed to produce a model of GSS, 
we created lines of mice carrying the P102L point mutation 
in both the MoPrP and HuPrP genes. The Tg(MoPrP- 
Pl 01 L)87 and Tg(MoPrP-Pl Ol L)174 mice expressing the 
mutant PrPC at high levels developed disease spontane- 
ously between 50 and 300 days of age (Hsiao et al., 1994). 
In contrast, a line designated Tg(HuPrP-PI 02L)FVB was 
observed for >700 days and, unlike the Tg(MoPrP-PI01 L) 
mice, did not develop spontaneous neurologic disease. 
The successful transmission of human prions to Tg- 
(MHu2M)FVB mice prompted us to produceTg(MHueM- 
PlOl L)PrnpO’O  mice. Unlike the Tg(HuPrP-P102L) mice, 
these Tg(MHuPM-Pl Ol L) mice spontaneously developed 
neurologic disease (Figure 2). By 480 days, -90% of 
Tg(MHu2M-P101 L) mice developed CNS dysfunction. An 
intense, reactive astrocytic gliosis was found in the gray 
matter of all mice expressing the MHu2M-PI01 L transgene 
at the time they exhibited CNS dysfunction (Figures 3A- 
3C). Modest spongiform degeneration and PrP immunore- 
activity were found in the white matter of all mice exam- 
ined. Besides the Tg(HuPrP-P102L)FVB mice, additional 
controls include Tg(HuPrP)FVB, Tg(MHu2M)FVB, and 
Tg(MHu2M)Prnp”jo mice, none of which has developed 
CNS degeneration spontaneously. Whether Tg(HuPrP- 
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Pl 02L)Prnp”‘o mice will develop a CNS illness spontane- 
ously is currently under study. 
Transmission of GSS Human Prions 
to Tg(MHuPM-PlOlL) Mice 
Although the Tg(MHu2M-Pl Ol L)PrnpO’O  mice eventually 
develop a spontaneous neurologic disorder, we asked 
whether illness might appear more rapidly after inocula- 
tion. These mice were inoculated at -70 days of age with 
brain extract from a GSS patient with the P102L mutation 
or from two sporadic CJD cases. The mice inoculated with 
GSS prions died after - 171 days (Figure 2) at a mean 
age of 247 days, which was >lOO days earlier than the 
age at which uninoculated controls developed CNS dys- 
function. Although theTg(MHuPM-PlOl L) mice inoculated 
with prions from sporadic CJD cases have a mean incuba- 
tion time of 259 days, these mice were 350 days of age 
at the time of death. The age of these mice prevented us 
from concluding whether they became ill from the inocu- 
lated prions or spontaneously as a result of expression of 
the MHuPM PrP-P102L mutant protein. 
Our  findings demonstrate that human prions from the 
GSS patient carrying the point mutation homologous to 
that in the transgene caused disease more rapidly than 
did wild-type human prions from sporadic cases of CJD. 
Conversely, the human prions from the GSS patient have 
failed to produce disease >310 days after inoculation in 
Tg(MHu2M)PrnpO’O  mice (Table 4, bottom), whereas hu- 
man prions containing wild-type PrPSc cause disease in 
Tg(MHu2M)PrnpO” mice at - 190 days (Table 4, middle). 
The onset of illness in the GSS-inoculated mice was rela- 
t ivelysynchronous, with a range of 30 days, while the onset 
was less uniform in the spontaneously ill and CJD- 
inoculated Tg(MHu2M-PlOl L)PrnpO’O  mice, with ranges of 
210 and 157 days, respectively. 
Figure 3. Spongiform Degeneration, Reactive 
Astrocytic Gliosis, and PrP lmmunostaining in 
Mice Expressing the Chimeric Mutant 
Transgene Designated MHu2M PrP-PlOlL 
Mice were sacrificed when they showed signs 
of CNS dysfunction. 
(A-C) Tg(MHu2M-Pl Ol L)69/PrnpoR mouse de- 
veloping CNS dysfunction spontaneously. 
(A) Section of hippocampal CA1 region stained 
with hematoxylin and eosin. 
(B) Reactive astrocytic gliosis is shown in a se- 
rial section of the hippocampal CA1 region 
stained for GFAP by immunoperoxidase. 
(C) PrP immunoreactivity in another serial sec- 
tion demonstrated by hydrolytic autoclaving. 
(D-F) Tg(MHu2M-PlOl L)69/PmpoD mouse de- 
veloping CNS dysfunction after inoculation 
with brain homogenate from a patient who died 
of GSS and carried the P102L mutation, 
(D) Section of hippocampal CA1 region stained 
with hematoxylin and eosin. 
(E) Reactive astrocytic gliosis is shown in a se- 
rial section of the hippocampal CA1 region 
stained for GFAP by immunoperoxidase. 
(F) PrP immunoreactivity in another serial sec- 
tion demonstrated by hydrolytic autoclaving. 
Magnification, 400 x 
Tg(MHu2M-Pl Ol L) mice inoculated with GSS prions ex- 
hibited spongiform degeneration and reactive astrocytic 
gliosis similar to uninoculated Tg(MHu2M-PI01 L) mice 
that developed CNS dysfunction spontaneously (Figures 
3D-3F). However,  the inoculated mice showed more neu- 
ronal loss and more intense and widespread glial fibrillary 
acidic protein (GFAP) immunostaining than uninoculated, 
spontaneously ill mice. PrP accumulation was more in- 
tense in some gray matter regions, such as the hippocam- 
pus, in the Tg(MHu2M-Pl Ol L) mice inoculated with GSS 
prions than in the uninoculated animals exhibiting sponta- 
neous illness. 
Uninoculated Tg(MHu2M-Pl Ol L)Prnp”O  mice that de- 
veloped CNS dysfunction did not have detectable prote- 
ase-resistant PrP (PrP 27-30) (Figure 4, lanes 8 and lo), 
similartoTg(MoPrP-PlOlL) mice(Hsiaoet al., 1994). Like- 
wise, the brain of the GSS patient from which the inoculum 
was derived contained little or no detectable PrP 27-30, 
even though numerous PrP amyloid plaques were found 
(Hsiaoetal., 1989)(Figure4,lane8). Inaddition,Tg(MHuPM- 
PlOl L)PrnpO’O  mice inoculated with brain homogenate 
from the GSS patient had no PrP 27-30 at the time of 
sacrifice after development of CNS dysfunction (Figure 4, 
lanes 12 and 14). The relatively short incubation times 
(Figure 2) recorded in the Tg(MHu2M-Pl Ol L)PrnpO’O  mice 
argue that the GSS brain contained high prion titers, even 
if PrP 27-30 was difficult to detect. From these results, 
we conclude that PrPSc containing the P102L mutation is 
probably less protease resistant than wild-type PrP (Figure 
4, lane 4) or PrP carrying other mutations. 
Transmission of Familial CJD(E2OOK) Human Prions 
to Tg(MHu2M) Mice 
Having found that homology between PrPC and PrPSc in 
the central domain profoundly affects prion transmission 
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Figure 4. Western Blot of Brain Homogenates from Transgenic Mice 
Expressing Chimeric PrP with the PlOlL Mutation That Causes GSS 
Tg(MHuPM-P102L)89/Prnp~” mice developed neurologic dysfunction 
spontaneously or after inoculation with brain homogenate from a GSS 
patient with the P102L mutation. Aliquots of brain homogenates from 
ill mice were either untreated (odd-numbered lanes) or digested with 
20 r.rg of proteinase K for 60 min at 37% (even-numbered lanes). 
Samples were resolved by SDS-polyacrylamide gel electrophoresis 
and analyzed by Western blot. The blot was exposed to anti-PrP 3F4 
MAb, developed using enhanced chemiluminescence (Amersham 
Corporation), and exposed to X-ray film. Lanes 1 and 2, normal human 
brain; lanes 3 and 4, sporadic CJD; lanes 5 and 6, GSS patient with 
a codon 102 proline to leucine PrP mutation; lanes 7-10, Tg(MHuPM- 
P102L)69/Prnp0m mice developing neurologic dysfunction spontane- 
ously; lanes 11-14, Tg(MHu2M-P102L)69/PrnpD’0 mice developing 
neurologic dysfunction after inoculation with brain homogenate from 
a GSS patient with the P102L mutation. The positions of protein molec- 
ular mass markers are shown to the left of the blot and correspond 
to molecular masses of (from top to bottom) 45, 31, 21, and 14 kDa. 
and that PrPC appears to interact through residues be- 
tween 215 and 230 with protein X, we examined the effect 
of an amino acid substitution within the region separating 
these two domains. Brain extracts were prepared from 
three patients who carried the E200K mutation and died 
of CJD (Gabizon et al., 1993) and inoculated intoTg(MHu2M) 
PrnpO’O  mice. Two extracts produced disease in - 175 
days, which is as rapid as those from sporadic CJD cases 
(Table 4). At the time of writing, a third CJD(E200K) case 
had not transmitted to Tg(MHu2M)PrnpO’O  mice after >290 
days. It is notable that the two cases that transmitted are 
M/M at codon 129, while the third is M/V with the E200K 
mutation on the allele encoding M at codon 129. 
The concept of the species barrier for prion transmission 
was introduced three decades ago based on transmission 
studies of experimental scrapie in sheep, goats, and ro- 
dents (Pattison, 1965). The initial molecular studies of the 
prion species barrier were performed using Tg(SHaPrP) 
mice (Prusiner et al., 1990; Scott et al., 1969). The SHaPrP 
transgene rendered mice susceptible to Syrian hamster 
prions, implying that the species barrier between Syrian 
hamsters and mice is due to one or more of the 16 amino 
acid substitutions that distinguish SHaPrP from MoPrP. 
Like Syrian hamster prions, human prions inoculated into 
nontransgenic mice produced disease infrequently after 
a prolonged incubation period. Based on our experience 
with Tg(SHaPrP) mice, we produced Tg(HuPrP) mice, but, 
surprisingly, they remained refractory to human prions. 
When the Tg(HuPrP) mice were crossed with Prnp”jo mice 
in which the MoPrP was disrupted, the resulting Tg(HuPrP) 
PrnpWO mice became susceptible to infection with human 
prions (Table 3). This indicates that MoPrPC inhibited the 
conversion of HuPrPC into HuPrPSc. These findings and 
others described here make it likely that besides PrPC and 
PrPSc a third component participates in the formation of 
nascent PrPSc. We presume that this third component is 
a macromolecule and that it is a protein; although it re- 
mains as yet unidentified, we have provisionally desig- 
nated this third component protein X. 
The site at which PrPC binds to protein X must be within 
the mouse-encoded residues of chimeric PrPC, since 
Tg(MHu2M) mice were found to be susceptible to human 
prions irrespective of the presence of endogenous MoPrPC 
(Table 4). We interpret these results to mean that the 
mouse sequences in chimeric PrPC enable it to compete 
effectively with MoPrPC for binding to protein X. 
We envision that during the propagation of prions a com- 
plex of homotypic PrPSc and PrPC binds to protein X. This 
pairwise interaction of PrPS” with PrPC and the stoichiome- 
try of the conversion reaction makes it doubtful that PrPS” 
itself is protein X. Although the function of protein X in the 
formation of PrPSc is unknown, it seems likely that protein 
X acts in some manner to facilitate the formation of na- 
scent PrPSc. 
PrPSc Formation 
The formation of nascent PrPSc is a posttranslational pro- 
cess (Borchelt et al., 1990; Taraboulos et al., 1995) that 
seems to occur after PrPC reaches the cell surface 
(Caughey and Raymond, 1991; Stahl et al., 1967). Trans- 
genetic studies argue that PrPC and PrPSc form a complex 
during the conversion of PrPC into nascent PrPSc (Prusiner 
et al., 1990; Scott et al., 1993). Although SHa transgenes 
provided considerable information about some of the fea- 
tures of PrPSc formation, use of the more divergent HuPrP 
transgene has greatly extended our understanding. 
Tg(MHu2M)PrnpO’O  mice that express only chimeric PrPC 
were resistant to mouse prions, whereas Tg(MHu2M)FVB 
mice expressing both chimeric and MoPrPCwere suscepti- 
ble to mouse prions, but the incubation time was prolonged 
(Telling et al., 1994). In contrast, Tg(MHuPM)PrnpO’O  mice 
inoculated with either human or chimeric MHu2M prions 
exhibited similar incubation times (Tables 4 and 5). 
To assess the specificity of PrPC binding to PrPSC in the 
central domain delimited by codons 96 to 167, we studied 
the influenceof pathologic mutationsand a polymorphism. 
Tg(MHu2M) mice were resistant to human prions from a 
patient with GSS who carried the PlO2L mutation, but 
were susceptible to prions from patients with familial CJD 
who harbor the E200K mutation (Table 4, bottom). Engi- 
neering the Pl02L mutation into the chimeric transgene 
rendered the Tg(MHuPM-PlOlL) mice susceptible to the 
GSS prions from the brain of a patient who died of GSS 
and carried the P102L mutation (Figure 2). Studies of 
Tg(HuPrP)PrnpO’O  mice expressing M or V at the polymor- 
phic codon 129 demonstrated the influence of this residue 
within the central domain on prion propagation (Figure 1). 
When the 129 residue within the central domain was the 
same .in PrPS” of the inoculum and PrPC of the recipient 
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mouse, incubation times were substantially shortened. 
These findings demonstrate that single amino acid mis- 
matches at codon 102 or 129 prolong the incubation time, 
whereas a mismatch at codon 200 does not. Although 
the results reported here argue that prion propagation is 
facilitated by homology within the central domains of HuPrPC 
and HuPrPSC, other investigations with SHalMoPrP trans- 
genes demonstrate that the requirements for sequence 
similarity may vary with different species and strains of 
prions (M. S. and S. 6. P., unpublished data). 
Stoichiometry of PrP and Protein X 
Although much of the specificity observed in nascent prion 
formation involves the formation of a PrPC-PrPSc complex, 
the putative interaction of PrPC with protein X provides an 
additional level of specificity. Since MoPrPC is present at 
lo%-20% of the level of HuPrPC in the brains of Tg(HuPrP) 
FVB mice, this excludes any simple model in which non- 
productive dimers of HuPrPC-MoPrPC are formed. In fact, 
it argues that there is an additional component that is criti- 
cal, i.e., protein X, for the conversion process and which 
is present at lower levels than HuPrPC. Since MoPrPC can 
effectively inhibit the formation of HuPrPSC, the level of 
protein X is equal to or less than that of MoPrPC. Based 
on the resistance of Tg(HuPrP)Prnp+“’ mice to human pri- 
ons, the level of protein X must be <500/o of the level of 
MoPrPC found in wild-type mice. Mice that are hemizygous 
for disruption of the MoPrP gene express -50% less 
MoPrPC. Even though the level of protein X is considerably 
lower than that of PrPC, it is still not rate limiting, since 
overexpression of SHaPrPC or MoPrPC increased the rate 
of PrPSc formation, as reflected by abbreviated incubation 
times in transgenic mice (Carlson et al., 1994; Prusiner 
et al., 1990). 
Since MoPrPC can inhibit the formation of HuPrPSc in the 
presence of a substantial excess of HuPrPC, this suggests 
that mouse protein X has a higher affinity for MoPrPC than 
for HuPrPC (Table 3, middle and bottom). MoPrPC pre- 
vented HuPrPScformation whetherthe inoculum contained 
amorphous aggregates of PrPSC or ordered arrays of prion 
rods composed of PrP 27-30 molecules (Table 3, top). If 
MoPrPC had been more inhibitory when the prion rods 
were inoculated, then we would suppose that a single 
MoPrPC molecule could bind to multiple HuPrPSc mole- 
cules and prevent the formation of nascent HuPrPSC, but 
this is not the case. 
We assume that the stoichiometry of PrPC and PrPSc 
that form a complex is approximately 1 :l. Whether this 
complex is composed of two or more PrP molecules is 
uncertain. Although some investigators have argued that 
the formation of nascent PrPSc involves the formation of 
PrP amyloid fibrils (Gajdusek, 1993; Jarrett and Lansbury, 
1993), there is much evidence to the contrary. Purified 
preparations of PrPSc possess an amorphous ultrastruc- 
ture and do not form amyloid polymers except when PrPSC 
undergoes partial proteolysis to produce PrP 27-30 in the 
presence of a nondenaturing detergent (McKinley et al., 
1991; Pan et al., 1993). Isolated PrP amyloid plaques con- 
tain primarily fragments of PrP (Kitamoto et al., 1991; Tag- 
liavini et al., 1994), and several synthetic PrP peptides 
spontaneously polymerize into amyloids when dispersed 
in water (Nguyen et al., 1995; Zhang et al., 1995). In vitro 
conversion of PrPC into a protease-resistant form pre- 
sumed to be equivalent to PrPSC by mixing a >50-fold ex- 
cess of PrPSc with labeled PrPC has been reported (Kocisko 
et al., 1994). Interestingly, the binding of PrPC to PrPSc 
was found to be dependent on the same residues that 
render Tg(MH2M) mice susceptible to Syrian hamster pri- 
ons (Scott et al., 1993; Kocisko et al., 1995) and seems 
to be strain dependent (Bessen et al., 1995). Whether PrPC 
actually undergoes a conformational change that is char- 
acteristic of PrPSC, or the binding of PrPC to PrPSc renders 
it protease resistant without actually undergoing this con- 
formational transition, remains to be established. With a 
different experimental protocol, mixing equimolar amounts 
of PrPC and PrPSc did not result in the conversion of PrPC 
into PrPSC (Raeber et al., 1992). 
Evidence for Protein X Binding to the C-Terminus 
of PrPC 
Since truncation experiments show that the N-terminal 67 
residues of mature PrP are dispensable (Rogers et al., 
1993), it seems likely that the site at which PrPC binds to 
protein X is at the C-terminal end of PrPC. A comparison of 
predicted amino acid sequences (Westaway et al., 1987) 
shows sufficient variation from codon 167 to 231 between 
Hu and MoPrP, as well as similarity between SHa and 
MoPrP, to account for our results. The location of residue 
215 is particularly interesting; in HuPrP it is an I, while in 
MoPrP it is a V and in SHaPrP a T. 
In contrast with SHaPrP, HuPrP differs from MoPrP at 
four additional amino acids that lie C-terminal to residue 
215. Any or all of these substitutions besides residue 215 
could explain the difference in susceptibility between 
Tg(HuPrP)FVB and Tg(SHaPrP)FVB mice to human and 
Syrian hamster prions, respectively. Two of the four addi- 
tional residues that distinguish HuPrP from MoPrP lie at 
positions 219 and 220. While these residues might partici- 
pate in the binding of PrPC to protein X, it seems unlikely 
that residues at 228 or 230 are involved in the binding to 
protein X, since they are adjacent to the glycosylphospha- 
tidylinositol anchor that is attached to an S residue at 231. 
The proposed model is consistent with our findings that 
chimeric MHu2M PrPC but not HuPrPC is converted into 
PrPSc in the presence of MoPrPC and that HuPrPC is con- 
verted into PrPSc in the absence of MoPrPC (Table 3). 
Does PrPSc Bind Protein X? 
The transmission of human and MHu2M prions into 
Tg(MHu2M)FVB mice yielded similar incubation times. 
This finding argues that the differences in the human or 
mouse sequences of PrPSc at the N- and C-termini have 
little effect on the transmission of prions to Tg(MHu2M) 
mice (Tables 3 and 4). Conversely, the region of PrP con- 
taining residues 96 to 167 clearly governs prion transmis- 
sion to Tg(MHu2M)PrnpO” mice: inoculation of human or 
MHuPM prions produced disease, but mouse prions did 
not. The apparent lack of binding of PrPSc to protein X is 
consistent with PrPSc being the product of the reaction and 
protein X facilitating the conformational change. 
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Is Protein X Distinct from PrPSC? 
Besides the evidence delineated above, other results also 
argue that protein X is not PrPSc. Although Tg(HuPrP) 
Prnp”” mice express the transgene product at levels 4-to 
8-fold higher than Tg(MHu2M)PrnpO’O  mice (Table i), the 
incubation times for human prions were similar in both 
transgenic lines (Tables 3 and 4). Since earlier studies 
demonstrated an inverse relationship between the level 
of PrPC expression and the incubation time (Prusiner et 
al., 1990), we conclude that chimeric PrPC is substantially 
more efficient in supporting prion propagation than 
HuPrPC. Although HuPrPSc initiates the conversion of chi- 
merit PrPC into PrPSc in Tg(MHu2M) mice, HuPrPSC be- 
comes a minor fraction of the total PrPSc, the vast majority 
of which is MHu2M PrPsG. Thus, it is difficult to attribute 
these results to the higher avidity of HuPrPSC for MHu2M 
PrPC than for HuPrPC; instead, the binding of mouse pro- 
tein X to chimeric PrPCwith a higher avidity than to HuPrPC 
seems a more reasonable explanation. 
If protein X does not exist, some alternative mechanism 
must also be invoked to explain the results of studies with 
uninoculated mice expressing PrP transgenes encoding 
the PlO2L mutation of GSS. When the PlO2L mutation 
was introduced through a mutant HuPrP transgene, the 
Tg(HuPrP-Pl02L)FVB mice did not become ill spontane- 
ously (see Results). In contrast, introduction of the muta- 
tion through a mutant MoPrP transgene readily produced 
spontaneous disease in Tg(MoPrP-PlOlL) mice (Hsiao et 
al., 1990, 1994). Since no PrPSc was inoculated into the 
mice, we cannot use binding of this isoform as an explana- 
tion for why the Tg(HuPrP-Pl02L)FVB mice did not be- 
come ill and those expressing mutant MoPrPC did. Indeed, 
it seems likely that wild-type MoPrPC in Tg(HuPrP-Pl02L) 
FVB mice may have prevented the interaction of mutant 
HuPrP with mouse protein X, which in turn prevented 
disease. 
Although the evidence speaks to the existence of protein 
X, only when protein X has been identified, and either the 
conditions defined for its functioning in vitro or the gene 
encoding it ablated (thereby rendering mice resistant to 
prions), will protein X be shown to be distinct from PrPSc. 
If progressive subcortical gliosis proves to be an inherited 
prion disease without a PrP gene mutation, then perhaps 
the mutant gene responsible for this disease encodes pro- 
tein X (Petersen et al., 1995). 
Does Protein X Function as a Molecular Chaperone? 
How PrPC unfolds and refolds into PrPSc is unknown (Pan 
et al., 1993), but the profound change in protein structure 
that occurs during this process is likely to be associated 
with a large activation barrier (Cohen et al., 1994). Whether 
protein X functions as a molecular chaperone that lowers 
this barrier remains to be established; consistent with such 
a role for protein X is the apparent lack of PrPSC binding. 
Changes in the inducibility of heat shock proteins (Hsp) 
as well as their subcellular distribution, some of which 
function as molecular chaperones (Georgopoulos and 
Welch, 1993), have been found in scrapie-infected cells 
(Tatzelt et al., 1995) and raise the poss/bility that protein 
X might be an Hsp. Notably, PrPSc itself has been sug- 
gested to function as a chaperone (Liautard, 1993). Alter- 
native possibilities for protein X include scaffolding or as- 
sembly proteins that provide a milieu for the PrP isoforms 
to interact, as well as the Bcl-2 protein, which was found 
to bind PrP using the yeast two-hybrid system (Kurschner 
and Morgan, 1995). Another possibility is that protein X 
features in the transient or as yet undetected chemical 
modification of PrPC that facilitates its refolding into PrPSc 
(Stahl et al., 1993). 
New Approaches to Studies of Prions 
Although many findings support the proposed mechanism 
for prion propagation involving protein X, it is of utmost 
importance to identify those proteins that bind to the PrPC- 
PrPSc complex and mediate a conformational change in 
PrPC. If PrPC binds to protein X through a domain near 
the C-terminus, as our data suggest, then systematic sub- 
stitution of residues in HuPrP with amino acids specified 
by MoPrP should facilitate identification of residues that 
modify susceptibility to human prions. Such experiments 
must consider the effects of single amino acid substitu- 
tions, which can cause conformational changes at a great 
distance along a polypeptide chain. Whether protein X is 
a single protein or a complex of proteins remains to be 
established. Once protein X is identified, then it may be 
possible to form prions in vitro and to determine the mech- 
anism of the conformational transition that underlies the 
conversion of PrPC into PrPSc. 
While most cases of human prion disease are not readily 
transmitted to Tg(HuPrP)FVB mice, an exception has been 
noted (Telling et al., 1994). Undoubtedly other such cases 
will be found, since it has been reported that a group of 
GSS cases harboring the PlO2L mutation transmit CNS 
degeneration to nontransgenic mice in <400 days while 
a second group of cases with the same genotype do not 
(Tateishi and Kitamoto, 1995). One explanation for these 
cases of prion disease, which are unusual with respect to 
their transmission characteristics, is that they represent 
different strains of prions. 
The concept of protein X in prion propagation, besides 
having practical ramifications for the bioassay of prions 
from humans as well as domestic animals such as cattle 
with bovine spongiform encephalopathy (Wells and Wile- 
smith, 1995), is intriguing with respect to understanding 
the function of PrPC. If, as recently suggested, several 
yeast proteins induce alternative metabolic states through 
a prion-like mechanism (Wickner, 1994), then perhaps 
PrPC also exists in more than one physiologic state. The 
transformation of PrPC to an alternative metabolic isoform 
might be facilitated by protein X. Interestingly, one prion- 
like protein in yeast (Sup35) seems to require intermediate 
levels of the molecular chaperone (Hspl04) to undergo 
transformation to [PSI+] (Chernoff et al., 1995). Might pro- 
tein X function as a chaperone that mediates a conforma- 
tional change in PrPC that alters its cellular function in the 
absence of PrPSc or a pathologic Pr? gene mutation? In 
the presence of PrPSc, protein X might catalyze the conver- 
sion of PrPC into PrPSC. Whatever the mechanism of PrPSc 
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formation, this process seems to be unprecedented in biol- 
ogy, and its elucidation promises to have implications far 
beyond the prion diseases. 
Experimental Procedures 
Production of Transgenic Mice 
The HuPrP-Ml29 and MHuSM-PlOlL transgenes were constructed 
by the same procedures described for the HuPrP-V129 and MHu2M 
PrP transgenes(Telling et al., 1994). Purified fragments containing the 
PrP ORF were ligated to the Sall-cut cos.SHa.Tet cosmid expression 
vector (Scott et al., 1992). Not1 fragments, recovered from large-scale 
DNA cosmid preparations, were used for microinjection into the pronu- 
clei of fertilized oocytes from FVB/N or PrnpofO mice as previously 
described (Scott et al., 1989). By crossing Tg(HuPrP)152/FVB, 
Tg(HuPrP)440/FVB, and Tg(MHu2M PrP)5378/FVB mice with PrnpO’O 
mice (Biieler et al., 1992) and subsequent backcrossing of these mice, 
Tg(HuPrP)Prnp”‘O and Tg(MHu2M PrP)PrnpO’O mice were produced. 
Genomic DNA isolated from tail tissue of weanling animals was 
screened for the presence of incorporated transgenes using a probe 
that hybridizes to the 3’ untranslated region of the SHaPrP gene con- 
tained in the cos.SHa.Tet vector (Scott et al., 1992) or for the ablated 
MoPrP gene by PCR (Prusiner et al., 1993). 
Genotyping of Patients 
Genomic DNA was extracted from frozen brains of autopsied patients 
or the leukocyte fraction from venous blood collected during life. To 
determine the codon 129 genotype, we performed allele-specific ampli- 
fication by running separate reactions using one of two sense strand 
primers matched to either M  or V by a single nucleotide change at 
the 3’end (GCCTTGGCGGCTACA for M  and GCCTTGGCGGCTACG 
for V). The antisense primer used in both reactions (AAGAATTCTCT- 
GACATTCTCCTCTTCA) lies within the ORF. A 500 bp product results 
from annealing of the sense strand primer, and no product results if 
annealing does not occur because of mismatch. Alternatively, DNA 
sequencing was used. 
Preparation of Brain Homogenates 
Homogenates (10% [w/v]) of mouse brain were prepared by repeated 
extrusion through an 18 gauge syringe needle followed by a 22 gauge 
needle in PBS lacking Ca- and Mg2+. The same procedure was used 
to prepare human brain homogenates, except that thawed brain tissue 
was initially disrupted with a sterile disposable homogenizer. Purified 
human prions were prepared using a protocol previously developed 
for Syrian hamster prions (Prusiner et al., 1983). 
Prion lnocula 
Human brain specimens were collected from patients dying of spo- 
radic, inherited, or infectious prion disease. The iatrogenic CJD case 
denoted 364 was provided by Dr. John Collinge. The RML isolate from 
Swiss mice (Chandler, 1961) was provided by Dr. William Hadlow and 
waspassaged in SwissCD-I miceobtainedfrom Charles River Labora- 
tories (Wilmington, MA). 
Measurement of Incubation Times 
Samples were diluted IO-fold in PBS prior to intracerebral inoculation 
of 30 pl. Criteria for diagnosis of scrapie in mice have been described 
elsewhere (Carlson et al., 1986). When CNS dysfunction appeared, 
the mice were examined daily. Histopathology was performed to con- 
firm the clinical diagnosis in selected cases. 
lmmunoblotting 
lmmuno dot blots for the determination of the relative levels of PrP 
expression in transgenic mouse brains were performed (Scott et al., 
1993). Enhanced chemiluminescent (ECL) detection (Amersham, Ar- 
lington Heights, IL) was used for Western blots. 3F4 MAb in ascites 
fluid (Kascsak et al., 1987) was used at a dilution of 1:5000. 
lmmunohistochemistry 
To enhance PrP immunoreactivity, the sections were immersed in 1.3 
mM HCI and autoclaved at 121% for 10 min (Muramoto et al., 1992). 
Staining was performed using the 3F4 MAb (Hecker et al., 1992). Im- 
munohistochemistry with antibodies to GFAP was used to evaluate 
the extent of reactive astrocytic gliosis. 
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